ba0007p133 | (1) | ICCBH2019
Bishop Nick
, Kalajzic Ivo
, Arshad Fawaz
, Lefley Diane
, Gossiel Fatma
, Ottewell Penny
Objectives: Losartan is an angiotensin II receptor type 1 (AT1) antagonist. Losartan reduces circulating TGFb concentrations in a variety of myopathic models. We hypothesised that losartan administration to the murine osteogenesis imperfecta model OIM would result in lower circulating TGFb and CTX (bone resorption marker) and increase bone mass.Methods: All procedures were approved by UConn Health Institutional Animal Care and Use Committee and performed...